Quattro Financial Advisors LLC Sells 95,781 Shares of Pfizer Inc. (NYSE:PFE)

Quattro Financial Advisors LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 56.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 75,000 shares of the biopharmaceutical company's stock after selling 95,781 shares during the period. Quattro Financial Advisors LLC's holdings in Pfizer were worth $1,900,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Norges Bank bought a new position in Pfizer in the fourth quarter worth approximately $2,328,986,000. Starboard Value LP bought a new position in Pfizer in the fourth quarter worth approximately $407,730,000. Raymond James Financial Inc. bought a new position in Pfizer in the fourth quarter worth approximately $274,694,000. Assenagon Asset Management S.A. raised its position in Pfizer by 307.5% in the first quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock worth $254,574,000 after acquiring an additional 7,581,030 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its position in Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company's stock worth $2,029,604,000 after acquiring an additional 5,350,381 shares during the period. Institutional investors own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on PFE shares. Wolfe Research increased their price target on shares of Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research report on Wednesday, April 30th. Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective on the stock. UBS Group raised their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. TD Cowen decreased their price objective on shares of Pfizer from $32.00 to $28.00 and set a "hold" rating on the stock in a research report on Tuesday, April 22nd. Finally, Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $28.55.

Pfizer Price Performance

Shares of NYSE:PFE traded up $0.13 on Friday, reaching $25.45. The company's stock had a trading volume of 27,104,580 shares, compared to its average volume of 41,722,894. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a market cap of $144.66 billion, a P/E ratio of 7.91, a PEG ratio of 0.92 and a beta of 0.58. The company has a 50-day simple moving average of $23.72 and a 200 day simple moving average of $24.83. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business's revenue was down 7.8% on a year-over-year basis. During the same quarter last year, the business earned $0.82 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.76%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.